Physician profile
Deepan Shailesh Dalal
NPI 1962720441
$122,037.47
in general payments reported to CMS, 2019-2025
34 companies · $29K in 2025
The $29K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100 · 2022: $16K · 2023: $48K · 2024: $29K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $17K · Food and Beverage: $14K · Travel and Lodging: $5,946 · Honoraria: $3,795 · Education: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,278.00 |
| Consulting Fee | $16,895.00 |
| Food and Beverage | $13,912.36 |
| Travel and Lodging | $5,945.96 |
| Honoraria | $3,795.00 |
| Education | $482.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $68,493.88 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $14,846.47 | 2022-2025 | Rinvoq, Skyrizi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,922.63 | 2023-2025 | Ofev, Cyltezo |
| Janssen Scientific Affairs, LLC | $8,148.49 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Horizon Therapeutics Plc | $5,461.70 | 2022-2023 | Krystexxa |
| Pfizer INC. | $4,493.38 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $2,900.00 | 2022-2025 | |
| Amgen INC. | $2,256.19 | 2022-2025 | Enbrel, Tavneos, Krystexxa |
| Ucb, INC. | $1,750.55 | 2022-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $1,450.30 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $653.58 | 2022-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $630.82 | 2022-2025 | Acthar |
| Sobi, INC | $353.46 | 2022-2025 | |
| Genentech USA, INC. | $312.60 | 2019-2023 | Actemra, Rituxan, Ocrevus |
| Lilly USA, LLC | $242.90 | 2022-2024 | Taltz, Zepbound |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $173.33 | 2023-2025 | |
| Organon LLC | $164.50 | 2024-2025 | Renflexis, Hadlima |
| Novartis Pharmaceuticals Corporation | $132.14 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $118.21 | 2024-2025 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $99.99 | 2023-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $88.81 | 2023-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $57.72 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, Ltd. | $42.98 | 2023 | Arcalyst |
| Aurinia Pharma U.S., INC. | $37.25 | 2023-2024 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $27.28 | 2024 | Onpattro |
| Cumberland Pharmaceuticals, INC. | $24.96 | 2022 | |
| Scilex Pharmaceuticals INC. | $24.15 | 2024 | |
| Hikma Pharmaceuticals USA | $21.57 | 2023 | Mitigare |
| Invivyd INC | $21.45 | 2025 | Pemgarda |
| Actelion Pharmaceuticals US, INC. | $20.82 | 2025 | Opsumit |
| Tonix Medicines, INC. | $18.35 | 2025 | Tonmya |
| Tersera Therapeutics LLC | $17.58 | 2025 | Quzyttir |
| Sandoz INC. | $15.93 | 2025 | Hyrimoz |
| Sanofi-Aventis U.S. LLC | $13.50 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepan Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.